At a glance
| Product | Sogroya |
|---|---|
| Target | GH receptor |
| Design | Albumin-binding long-acting analog |
| Pediatric minimum age | 2.5 years for labeled conditions |
| Key monitoring | Growth response and IGF-1 |
Overview
Sogroya provides prolonged GH activity through a modified molecule that binds albumin. Its adult indication is replacement in established growth-hormone deficiency. The current pediatric label includes growth failure from inadequate GH secretion, certain children born small for gestational age without catch-up growth, Noonan syndrome and idiopathic short stature. These are defined clinical diagnoses, not a general indication to increase height or improve body composition in otherwise healthy people. Weekly administration changes convenience and exposure patterns, but does not remove the endocrine evaluation, growth assessment or safety surveillance required for GH-directed treatment.
How it works
Somapacitan activates GH receptors in target tissues and stimulates downstream effects, including IGF-1 production. Reversible albumin binding prolongs exposure compared with unmodified somatropin. Some actions are mediated through IGF-1, while others reflect direct GH signaling. Because concentrations and IGF-1 vary across the weekly interval, the timing of biochemical assessment matters when interpreting response and avoiding excessive hormonal exposure.
Current approved populations
The 2026 label includes pediatric GH deficiency, selected SGA short stature, Noonan syndrome and idiopathic short stature from age 2.5, plus adult GH deficiency. The actual diagnostic criteria and growth-plate status determine eligibility.
Supporting sources [1]
How adult and pediatric benefit differ
The adult REAL-1 study evaluated body-composition and metabolic effects in GH deficiency. Pediatric studies assess annualized height velocity and growth outcomes against daily somatropin. Adult fat-mass findings and childhood linear growth are not interchangeable endpoints.
GH-related adverse effects
Fluid retention, glucose intolerance, intracranial hypertension and thyroid or adrenal-axis changes require attention. Pediatric monitoring includes hip or knee pain suggesting slipped capital femoral epiphysis and progression of scoliosis. Hypersensitivity can occur.
Supporting sources [1]
Important restrictions
Active malignancy, certain acute critical illnesses, severe diabetic retinopathy and closed growth plates for pediatric growth promotion are contraindications. Specific respiratory-risk restrictions apply to children with Prader-Willi syndrome, although that syndrome is not a general Sogroya growth indication.
Supporting sources [1]
Weekly GH is not a direct volume substitution
Long-acting GH analogs differ from daily somatropin and from each other. Their exposure patterns and IGF-1 interpretation are product-specific, so a change in formulation requires a clinical plan rather than simple conversion by injection volume.
Supporting sources [1]
Reading this profile
Jurisdiction: United States — FDA-approved prescription medicine; indication and formulation restrictions apply.. Molecular class: Long-acting albumin-binding growth-hormone analog protein.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- DailyMed: Sogroya current prescribing information ↗Regulatory source · Checked 2026-10-27
- Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial. ↗Original research · Checked 2026-10-27